RxDoctor Payments Data

Winston Crute, MD

Urology · Tuscaloosa, ALNPI 1922504331

Payments from drug & device makers

$6,797in general payments, 2019–2025

Across 205 payments — averaging $33.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Boston Scientific$687
  • AbbVie$413
  • Sumitomo Pharma America, Inc.$400
  • Medtronic$370
  • Coloplast$252
  • plus $2K from 28 others

What the payments were for

  • Travel & lodging$1,14517%
  • Food & beverage$5,65383%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,797 in reported general payments places this provider in the 60th percentile of 179 urology providers in Alabama.

See all urology providers in Alabama

Medicare billing

Part B allowed, 2024
$151,705
Medicare patients
421
Services billed
2,269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide19$266,890
Lupron DepotLeuprolide Acetate20$217,778
MyrbetriqMirabegron207$119,063
GemtesaVibegron169$116,565
Tamsulosin Hcl306$3,856
Estradiol53$3,184
Testosterone Cypionate50$1,172
Dutasteride19$923
Finasteride55$864
Potassium Citrate ErPotassium Citrate13$641
NitrofurantoinNitrofurantoin Macrocrystal32$526
Cephalexin71$414
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim163$342
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen131$284
Ciprofloxacin Hcl35$200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$82$385,953226 claims
AbbVieLupron Depot$413$217,77820 claims
Sumitomo Pharma America, Inc.Gemtesa$400$116,565169 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 179 urology providers in Alabama.

Other urology in Tuscaloosa

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →